quadraScope

Following the data **Key trends in the longevity science and market**


Fiona Miller 16-Nov-2022

quadraScope invests in ventures that aim to reverse aging and enhance health by targeting the mechanisms of aging.






Rejuvenation industry cycle






Relevant Nobel Prizes in the last 20 years





Significant increase in publications and trials




Source: NIH National Library of Medicine; <u>publications</u>, <u>clinical trials</u>. Search terms: "rejuvenation", "aging", "longevity".




\$490B global spending on age-related diseases

Global markets for age related diseases (2022): <u>dementia</u>, <u>stroke</u>, <u>atherosclerosis</u>, <u>hypertension</u>, <u>chronic kidney disease</u>, <u>diabetes</u>, <u>cancer</u>, <u>sarcopenia</u>, <u>osteoporosis</u>, <u>osteoarthritis</u>, <u>macular degeneration</u>, <u>cataracts</u>, <u>COPD</u>, <u>hearing loss</u>.



\$1 trillion market opportunity to displace ...




quadraScope

Significant growth in new aging-related ventures and investments


Longevity company formations

Investments in longevity companies (\$B)





Further validated by most recent funding surge



Jun 2021 **Second**

Google sister company and drug giant chip in another **\$1B** to cure age-related diseases – Calico

oct 2021 the pharmaletter

Cambrian Biopharma closes **\$100M** Series C to advance healthspan-boosting therapies

Dec 2021 **Yahoo**.

What this crypto billionaire's big bet on longevity means for you – NewLimit, **\$105M**

Dec 2021 The Economis

A **\$3B** bet on finding the fountain of youth – Altos Labs



Big pharma is investing in longevity


Notable partnerships (2021 and 2022)



BCG The emerging commercial landscape for aging biology-based therapeutics Analysis by Michael Ringel, JD, PhD

*Alphabet Inc. (Google) invested an additional \$500M in the same deal **\$20M upfront, Minovia may receive up to \$420M per product in milestone payments ***\$50M upfront, Lineage may receive up to \$670M in milestone payments Deal references: <u>AbbVie</u>, <u>Roche</u>, <u>Astellas</u>, <u>Novartis</u>.






quadraScope



Treatment modalities and impact on hallmarks of aging




Hallmarks of aging

Therapeutic potential



Rejuvenation medicine





Ferrucci L, et al. 2020.

Aging biomarkers – industry segmentation



Lead team: proven track record in building companies





Fiona Miller

Managing Partner

- Serial tech entrepreneur with 3 successful exits
- \$3.3M invested into
 9 rejuvenation ventures
- Board member at Healthy Longevity Clinic

José Navarro-Betancourt, MD, PhD

Scientific Director & Partner

- Peer reviewed publications on the mechanisms of aging
- PhD from McGill University



Advisors active in the rejuvenation ecosystem

Top international aging scientists, drug development experts, and longevity industry pioneers



Nir Barzilai, MD

- Renowned expert in longevity genomics
- Scientific director of the American
 Federation for Aging Research
- Professor at the Albert Einstein College of Medicine
- Lead investigator in the SuperAgers initiative and the TAME trail



Carmela Abraham, PhD

- Professor Emerita, Boston University
- Acclaimed expert in the biology of aging and Alzheimer's disease



Reason

- Co-founder and CEO of Repair Biotechnologies
- Active investor in longevity (Oisin Biotechnologies and Leucadia Therapeutics).



Diane Seimetz, PhD

- Leading drug development and regulatory expert
- Angel investor
- Board member at several biotech companies



Venture Partners



Frank Wellens

Venture Partner

- Over 20 years of experience in management consulting, M&A, and investing
- Invested and served on the board of the Managing Partner's last venture
- M.Sc. in applied economics from the University of Antwerp and advanced management program at Harvard Business School



Miri Polachek

Venture Partner

- Managed Joy Ventures, a mental health fund and venture builder
- Co-founded and ran Israel Brain Technologies, a brain technology accelerator and hub
- 30 years financial and operational leadership including big pharma (Pfizer, Teva)
- MA in Health Economics from Boston University and MBA from New York University




Daniel Fylstra

Venture Partner

- Founder and CEO of Frontline Systems Inc., a software company specialized in advanced analytics and decision intelligence
- Seed investor and former CEO of Sierra Sciences, a biotech company focused on telomere biology
- BS in EE & Computer Science from M.I.T. and MBA from Harvard Business School




Our focus: early-stage rejuvenation



Investment opportunity – Company A


Aiming to cure presbyopia using small molecules that restore the flexibility of the eye lens. The treatments may be applicable to other conditions associated with protein damage.





Near objects

The lens stretches and compresses to focus objects





Investment opportunity – Company B


Revolutionizing the

treatment of

osteoarthritis using

gene therapy to regenerate cartilage in

joints.








Investment opportunity – Company C

Synthesizing biomaterials

that serve as scaffolds

where cells attach,


proliferate, and generate new tissue.






Investment opportunity – Company D

Producing antibodies that specifically recognize senescent cells and promote the removal of these cells by the immune system.








Investment opportunity – Company E

Focused on the isolation, expansion, enhancement, and reinfusion of blood stem cells to reconstitute and rejuvenate the

immune system.





Investment opportunity – Company F

Small proteins that


selectively bind to


damaged collagen and

have the potential to

diagnose and treat fibrotic

diseases (e.g., liver cirrhosis).








Investment opportunity – Company G

Cellular reprogramming using vesicles produced by neural stem cells, which contain rejuvenation proteins, mRNAs, and microRNAs.






Investment opportunity – Company H

University spinout opportunity aiming to gradually and progressively replace aged brain cortex

tissue.









Investment opportunity – Company I

Developing an AI-enabled blood test for early detection of hard-todiagnose chronic diseases (e.g., chronic obstructive pulmonary disease).








Investment opportunity – Company J

Machine Learning technology that generates and analyzes complete multiomic profiles to capture a current health status, predict future conditions, and design personalized rejuvenation treatments.







- ✓ Genomics
- ✓ Epigenomics
- ✓ Transcriptomics
- Metabolomics
- Proteomics



Investment opportunity – Company K Israel

Non-invasive functional neuroimaging platform for early diagnosis of brain diseases via transcranial magnetic stimulation.







quadraScope key terms

Fund size Target: \$20M with 50% reserved for follow-on

Number of investments Target: 20

Stage Focus: Pre-Seed / Seed

Fund term 10 years + possible two 1-year extensions

Investment period Target: 5 years Minimum LP investment \$100,000

Carried Interest 20%

Management fee 2% per year

Manager contribution \$4M



quadraScope

Let's invest in healthy lifespans together

Fiona Miller Managing Partner <u>fm@quadrascope.com</u>

